Lv5
1520 积分 2023-12-21 加入
Development of a dual functional RNAi therapeutic, ARO-DIMER-PA, for mixed hyperlipidemia
1天前
待确认
Development of a dual functional RNAi therapeutic, ARO-DIMER-PA, for mixed hyperlipidemia
1个月前
已完结
Reversal of obesity by targeted ablation of adipose tissue
2个月前
已完结
Retinol-binding protein 4 in obesity and metabolic dysfunctions
4个月前
已完结
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
4个月前
已完结
The story of amylin: from physiology to therapy
4个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
4个月前
已完结
Phase III retatrutide study demonstrates 30% weight loss
4个月前
已关闭
A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy
4个月前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
4个月前
已完结
皖公网安备34019202002308
